Tyra Biosciences, a preclinical biotech developing FGFR inhibitors for cancer, filed on Friday with the SEC to raise up to $100 million.
Tyra Biosciences is a precision oncology company focused on developing purpose-built therapies for tumor resistance. The company is using its proprietary SNÅP platform to generate next-generation candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. It is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family. Its lead candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. Tyra anticipates filing an IND for TYRA-300 in mid-2022.
The Carlsbad, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol TYRA. Tyra Biosciences filed confidentially on May 28, 2021. BofA Securities, Jefferies, and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
